文献
J-GLOBAL ID:201702225963641192
整理番号:17A1638562
ICH M7オプション4制御戦略の実施を導くためのコンソーシアム駆動フレームワーク【Powered by NICT】
A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies
著者 (26件):
Barber Chris
(Lhasa Limited, Leeds, UK)
,
Antonucci Vincent
(Merck Sharp & Dohme, Rahway, NJ, USA)
,
Baumann Jens-Christoph
(F. Hoffmann-La Roche Ltd., Basel, Switzerland)
,
Brown Roland
(Pfizer, Sandwich, UK)
,
Covey-Crump Elizabeth
(Lhasa Limited, Leeds, UK)
,
Elder David
(Consultant, Hertford, Hertfordshire, UK)
,
Elliott Eric
(Takeda Pharmaceuticals, Cambridge, MA, USA)
,
Fennell Jared W.
(Eli Lilly and Co., Indianapolis, IN, USA)
,
Gallou Fabrice
(Novartis, Basel, Switzerland)
,
Ide Nathan D.
(AbbVie, North Chicago, IL, USA)
,
Jordine Guido
(Novartis, Basel, Switzerland)
,
Kallemeyn Jeffrey M.
(AbbVie, North Chicago, IL, USA)
,
Lauwers Dirk
(Janssen Pharmaceutica NV, Beerse, Belgium)
,
Looker Adam R.
(Vertex Pharmaceuticals, Boston, MA, USA)
,
Lovelle Lucie E.
(Novartis, Basel, Switzerland)
,
McLaughlin Mark
(Merck Sharp & Dohme, Rahway, NJ, USA)
,
Molzahn Robert
(Excella GmbH & Co. KG, Feucht, Germany)
,
Ott Martin
(Lhasa Limited, Leeds, UK)
,
Schils Didier
(Galapagos NV, Mechelen, Belgium)
,
Oestrich Rolf Schulte
(F. Hoffmann-La Roche Ltd., Basel, Switzerland)
,
Stevenson Neil
(GlaxoSmithKline, Stevenage, Hertfordshire, UK)
,
Talavera Pere
(Esteve Quimica, Barcelona, Spain)
,
Teasdale Andrew
(AstraZeneca, Macclesfield, Cheshire, UK)
,
Urquhart Michael W.
(GlaxoSmithKline, Stevenage, Hertfordshire, UK)
,
Varie David L.
(Eli Lilly and Co., Indianapolis, IN, USA)
,
Welch Dennie
(AbbVie, North Chicago, IL, USA)
資料名:
Regulatory Toxicology and Pharmacology
(Regulatory Toxicology and Pharmacology)
巻:
90
ページ:
22-28
発行年:
2017年
JST資料番号:
T0249A
ISSN:
0273-2300
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)